T-Cell Lymphomas - Pipeline Review, H1 2012

Global Markets Direct, April 2012, Pages: 262

T-Cell Lymphomas – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'T-Cell Lymphomas - Pipeline Review, H1 2012', provides an overview of the T-Cell Lymphomas therapeutic pipeline. This report provides information on the therapeutic development for T-Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas. 'T-Cell Lymphomas - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for T-Cell Lymphomas.
- A review of the T-Cell Lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the T-Cell Lymphomas pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for T-Cell Lymphomas.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding T-Cell Lymphomas pipeline depth and focus of T-Cell Lymphomas therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

T-Cell Lymphomas Therapeutic Products under Development, Key Players in T-Cell Lymphomas Therapeutics, T-Cell Lymphomas Pipeline Overview, T-Cell Lymphomas Pipeline, T-Cell Lymphomas Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
T-Cell Lymphomas Overview
Therapeutics Development
An Overview of Pipeline Products for T-Cell Lymphomas
T-Cell Lymphomas Therapeutics under Development by Companies
T-Cell Lymphomas Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
T-Cell Lymphomas Therapeutics – Products under Development by Companies
T-Cell Lymphomas Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in T-Cell Lymphomas Therapeutics Development
Kyowa Hakko Kirin Co., Ltd.
Abbott Laboratories
Amgen Inc.
Seattle Genetics, Inc.
Emergent BioSolutions Inc.
ZIOPHARM Oncology, Inc.
Millennium Pharmaceuticals, Inc.
Cephalon, Inc.
Eisai Co., Ltd.
Celgene Corporation
Incyte Corporation
Allos Therapeutics, Inc
BioCryst Pharmaceuticals, Inc.
TopoTarget A/S
Pharmacyclics, Inc.
Sareum Holdings plc
Chipscreen Biosciences Ltd
Xencor, Inc.
PharmaMar, S.A.
T-Cell Lymphomas – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ABT-263 - Drug Profile
MLN8237 - Drug Profile
Adcetris - Drug Profile
Adcetris - Drug Profile
Chidamide - Drug Profile
Belinostat - Drug Profile
KW-0761 - Drug Profile
PCI-34051 - Drug Profile
Jakafi - Drug Profile
Forodesine - Drug Profile
Zinapar - Drug Profile
Ontak - Drug Profile
Folotyn - Drug Profile
XmAb2513 - Drug Profile
Zanolimumab - Drug Profile
Aplidin - Drug Profile
Lenalidomide - Drug Profile
Revlimid + Zolinza + Dexamethasone - Drug Profile
Clofarabine - Drug Profile
Poly-ICLC + Low Dose Local Radiation - Drug Profile
Campath-1H + CHOP - Drug Profile
Alemtuzumab + CHOP + ESHAP - Drug Profile
CHOP-14 + Alemtuzumab - Drug Profile
C-CHOP - Drug Profile
Romidepsin - Drug Profile
Vorinostat + Azacitidine - Drug Profile
Dexamethasone + Ifosfamide + Cisplatin + Etoposide - Drug Profile
Folotyn + Gemcitabine Hydrochloride - Drug Profile
SGN-35 + Rifampin - Drug Profile
SGN-35 + Ketoconazole - Drug Profile
Revlimid - Drug Profile
Lenalidomide + Vorinostat + Dexamethasone - Drug Profile
Rituximab + Siplizumab + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Vincristine + Filgrastim - Drug Profile
CHOP14 + G-CSF + MabCampath + Autologous Stem Cell Transplantation - Drug Profile
UCN-01 - Drug Profile
Fludarabine + Doxorubicin + Dexamethasone - Drug Profile
Asparaginase + Cyclophosphamide + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Mercaptopurine + Methotrexate + Methylprednisolone + Mitoxantrone Hydrochloride + Prednisone + Vincristine Sulfate + Radiation Therapy - Drug Profile
Roferon + Accutane - Drug Profile
Zolinza + CHOP - Drug Profile
RAD001 + Revlimid - Drug Profile
Busulfan + Cyclophosphamide + Etoposide + Radiation Therapy + Bone Marrow Transplantation - Drug Profile
Cisplatin + Etoposide + Gemcitabine + Solumedrol - Drug Profile
Cyclophosphamide + Etoposide + Allogeneic Bone Marrow Transplantation + Radiation Therapy - Drug Profile
Cyclophosphamide + Hydroxydaunorubicin + Vincristine + Prednisone + G-CSF + Alemtuzumab - Drug Profile
Etoposide + Vincristine + Doxorubicin + Prednisone + Cyclophosphamide + Bortezomib + Raltegravir - Drug Profile
L-Asparaginase + Methotrexate + Dexamethasone - Drug Profile
HCVIDDOXIL + Methotrexate + Ara-C - Drug Profile
Bendamustine - Drug Profile
MEDI-507 - Drug Profile
Treanda + Carboplatin + Rituximab + Etoposide - Drug Profile
Nelfinavir + Bortezomib - Drug Profile
Ara-C + Cyclophosphamide + Fludarabine + Busulfan + Total Body Irradiation + Cord Blood Transplantation - Drug Profile
Etoposide + Doxorubicin + Vincristine + Cyclophosphamide + Prednisolone - Drug Profile
Istodax - Drug Profile
RAD001 + CHOP - Drug Profile
Busulfan + Cyclophosphamide + Allogeneic Bone Marrow Transplantation + Methylprednisolone + Methotrexate + Cyclosporine - Drug Profile
SMILE - Drug Profile
Lenalidomide + Rituximab + Carmustine + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplant - Drug Profile
IMTOX25 - Drug Profile
Etoposide + Prednisone + Vincristine + Cyclophosphamide + Doxorubicin + Lamivudine + Zidovudine + Interferon Alfa - Drug Profile
Endostar + CHOP - Drug Profile
CHOEP + G-CSF + BEAM - Drug Profile
Carmustine + Etoposide + Cytarabine + Fludarabine Phosphate + Cyclophosphamide + Tacrolimus + Mycophenolate Mofetil + Melphalan + Filgrastim + Stem Cell Transplantation + Radiation Therapy - Drug Profile
Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Etoposide + Ifosfamide + Leucovorin Calcium + Methotrexate + Therapeutic Hydrocortisone + Vinblastine - Drug Profile
CHOP + Campath-1H - Drug Profile
Campath-1H + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Prednisone + Vincristine Sulfate - Drug Profile
Nelarabine + Etoposide + Cyclophosphamide + Methotrexate + Filgrastim - Drug Profile
Amevive - Drug Profile
Vidaza + Velcade - Drug Profile
PF02341066 - Drug Profile
Busulfan + Etoposide + Cyclophosphamide + Fludarabine + Mesna + Phenytoin + Ursodiol + Autologous Peripheral Blood Stem Cells + Neupogen + Allogenic Peripheral Blood Stem Cell Transplant + Tacrolimus + Sirolimus + Methotrexate - Drug Profile
FK228 - Drug Profile
Gemcitabine + Navelbine + Doxil + G-CSF + Cyclophosphamide + Vincristine + Prednisone + Autologous Stem Cell Transplantation + Ontak - Drug Profile
CEP-37440 - Drug Profile
Istodax + CHOP - Drug Profile
Fludarabine + Cytarabine + Busulfan/Melphalan+ Antithymocyte Globulin + Cyclophosphamide + Tacrolimus + Mycophenolate Mofetil + Stem Cell Transplantation - Drug Profile
SGN-35 + Cyclophosphamide + Prednisone + Doxorubicin + Vincristine - Drug Profile
AMG 319 - Drug Profile
Aurora + ALK Program - Drug Profile
Carfilzomib - Drug Profile
Cisplatin + L-Asparaginase + Methotrexate + Ifosfamide + Dexamethasone + Etoposide + Radiation Therapy - Drug Profile
SGN-35 + Cyclophosphamide + Prednisone + Doxorubicin - Drug Profile
Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile
Bortezomib - Drug Profile
Bone Marrow Transplantation - Drug Profile
Peripheral Blood Stem Cell Transplantation - Drug Profile
IMTOX-25 - Drug Profile
KW-0761 + mLSG15 - Drug Profile
LBH589 - Drug Profile
Alemtuzumab + Fludarabine + Cyclophosphamide + Doxorubicin - Drug Profile
T-Cell Lymphomas Therapeutics – Drug Profile Updates
T-Cell Lymphomas Therapeutics – Discontinued Products
T-Cell Lymphomas Therapeutics - Dormant Products
T-Cell Lymphomas – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for T-Cell Lymphomas, H1 2012
Products under Development for T-Cell Lymphomas – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Kyowa Hakko Kirin Co., Ltd., H1 2012
Abbott Laboratories, H1 2012
Amgen Inc., H1 2012
Seattle Genetics, Inc., H1 2012
Emergent BioSolutions Inc., H1 2012
ZIOPHARM Oncology, Inc., H1 2012
Millennium Pharmaceuticals, Inc., H1 2012
Cephalon, Inc., H1 2012
Eisai Co., Ltd., H1 2012
Celgene Corporation, H1 2012
Incyte Corporation, H1 2012
Allos Therapeutics, Inc, H1 2012
BioCryst Pharmaceuticals, Inc., H1 2012
TopoTarget A/S, H1 2012
Pharmacyclics, Inc., H1 2012
Sareum Holdings plc, H1 2012
Chipscreen Biosciences Ltd, H1 2012
Xencor, Inc., H1 2012
PharmaMar, S.A., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
T-Cell Lymphomas Therapeutics – Drug Profile Updates
T-Cell Lymphomas Therapeutics – Discontinued Products
T-Cell Lymphomas Therapeutics – Dormant Products
T-Cell Lymphomas Therapeutics – Dormant Products (Contd..1)
T-Cell Lymphomas Therapeutics – Dormant Products (Contd..2)
T-Cell Lymphomas Therapeutics – Dormant Products (Contd..3)

List of Figures
Number of Products under Development for T-Cell Lymphomas, H1 2012
Products under Development for T-Cell Lymphomas – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Natural Killer Cell Lymphomas – Pipeline Review, H1 2013
• Lymphoma - Pipeline Review, H2 2012
• Myeloproliferative Disorders - Pipeline Review, H2 2012
• Brain Cancer - Pipeline Review, H2 2012
• Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2012
• Non-Hodgkin Lymphoma - Pipeline Review, H2 2012
• Myelodysplastic Syndrome - Pipeline Review, H1 2012
• Thrombocytopenia - Pipeline Review, H1 2012
• Cytopenia - Pipeline Review, H2 2012
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2012